Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy

BACKGROUND: Prescribing anti-programmed death-1 (PD-1) immunotherapy for advanced melanoma is currently not restricted by any biomarker assessment. Determination of programmed death-ligand-1 (PD-L1)-expression status is technically challenging and is not mandatory, because negative tumours also achi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupuis, Frantz, Lamant, Laurence, Gerard, Emilie, Torossian, Nouritza, Chaltiel, Leonor, Filleron, Thomas, Beylot-Barry, Marie, Dutriaux, Caroline, Prey, Sorilla, Gros, Audrey, Jullie, Marie-Laure, Meyer, Nicolas, Vergier, Béatrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048096/
https://www.ncbi.nlm.nih.gov/pubmed/29973670
http://dx.doi.org/10.1038/s41416-018-0168-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048096/
https://www.ncbi.nlm.nih.gov/pubmed/29973670
http://dx.doi.org/10.1038/s41416-018-0168-9

Ejemplares similares